Qulipta and Vyepti Comparison

Qulipta®(atogepant)	Vyepti®(eptinezumab)
Prescription Only Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...	Prescription Only Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...
Administration
Oral. Learn more.	Intravenous Infusion. Learn more.
Dosing
10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.	Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.
Latin Shorthand
10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.	100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$0. Learn more.
Annual Cap
$6000. Learn more.	$200 per infusion administration fee. Learn more.
Assistance Expiration
12 30-day prescription fills. Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.	The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonists. Learn more.	CGRP Antagonist. Learn more.
Special Populations
Is QULIPTA safe to use during pregnancy? There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine. Is QULIPTA safe to use during lactation? There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition. Is QULIPTA safe to use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients. Is QULIPTA safe to use in elderly patients? Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Is QULIPTA safe to use in patients with hepatic impairment? No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment. Is QULIPTA safe to use in patients with renal impairment? The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.	Is it safe to use VYEPTI during pregnancy? There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy. Are there any risks to the fetus if the mother receives VYEPTI? Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively. Is it safe to breastfeed while using VYEPTI? There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding. Is VYEPTI safe for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients. Is VYEPTI safe for use in geriatric patients? Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.

Qulipta®(atogepant)

Vyepti®(eptinezumab)

Prescription Only

Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...

Prescription Only

Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...

Dosage & Administration

Administration

Oral. Learn more.

Intravenous Infusion. Learn more.

Dosing

10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.

Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.

Latin Shorthand

10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.

100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

Annual Cap

$6000. Learn more.

$200 per infusion administration fee. Learn more.

Assistance Expiration

12 30-day prescription fills. Learn more.

Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.

The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.

Mechanism of Actions (MoA)

CGRP Antagonists. Learn more.

CGRP Antagonist. Learn more.

Special Populations

Is QULIPTA safe to use during pregnancy?

There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine.

Is QULIPTA safe to use during lactation?

There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.

Is QULIPTA safe to use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients.

Is QULIPTA safe to use in elderly patients?

Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Is QULIPTA safe to use in patients with hepatic impairment?

No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment.

Is QULIPTA safe to use in patients with renal impairment?

The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.

Is it safe to use VYEPTI during pregnancy?

There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy.

Are there any risks to the fetus if the mother receives VYEPTI?

Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively.

Is it safe to breastfeed while using VYEPTI?

There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding.

Is VYEPTI safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients.

Is VYEPTI safe for use in geriatric patients?

Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.

Qulipta® Alternatives